文献速递肝病消化道肿瘤与早癌消化内镜

预防性地塞米松用于经导管动脉化疗栓塞的随机安慰剂对照试验

A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.
PubMed 文献 · Hepatology · 2017-12-23

这项随机双盲安慰剂对照试验纳入120例无大血管侵犯或肝外转移的Child-Pugh A/B级肝细胞癌患者,比较地塞米松方案与对照方案预防TACE所致发热、厌食和恶心呕吐的效果,主要终点为TACE后120小时内完全缓解率,地塞米松组47.5% vs 对照组10.2%(P<0.001)。

要点

  • 地塞米松方案完全缓解率47.5%(95%CI 34.3%-60.9%)vs 对照方案10.2%(95%CI 3.8%-20.8%),P<0.001。
  • 对照组发热、厌食累积发生率均高于地塞米松组(P<0.001和P<0.001),恶心呕吐两组P=0.095。
  • 地塞米松方案在包括糖尿病控制良好及乙型肝炎病毒感染的肝细胞癌患者中总体耐受良好。

核心结论

  • 地塞米松方案在预防肝细胞癌患者TACE所致发热、厌食和恶心呕吐方面比对照方案更有效。

研究设计与样本

  • 随机双盲安慰剂对照试验,纳入120例无大血管侵犯或肝外转移的Child-Pugh A/B级肝细胞癌患者,2010年10月至2013年6月随机分组。

主要发现

  • 总体完全缓解率地塞米松方案组为47.5%(95%CI 34.3%-60.9%),对照方案组为10.2%(95%CI 3.8%-20.8%),P<0.001。
  • 发热累积发生率对照组高于地塞米松组(P<0.001)。
  • 厌食累积发生率对照组高于地塞米松组(P<0.001)。
  • 恶心呕吐累积发生率对照组高于地塞米松组(P=0.095)。
  • 地塞米松方案在包括糖尿病控制良好及乙型肝炎病毒感染的肝细胞癌患者中总体耐受良好。

关键数值与推荐

  • 地塞米松方案:第1天TACE前静脉给予地塞米松20 mg和格拉司琼3 mg;第2天和第3天静脉给予地塞米松8 mg。
  • 对照方案:第1天静脉给予安慰剂(生理盐水)和格拉司琼3 mg;第2天和第3天静脉给予安慰剂。
  • 主要终点完全缓解定义为TACE后120小时内无≥1级发热、厌食或恶心呕吐(按不良事件通用术语标准4.0版)且未使用挽救治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This randomized, double-blind, placebo-controlled trial evaluated dexamethasone efficacy at preventing fever, anorexia, and nausea/vomiting, the most frequent adverse events of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Child-Pugh class A/B patients with HCC and no macrovascular invasion/extrahepatic metastases were randomly assigned to either a dexamethasone regimen (day 1, intravenous dexamethasone [20 mg] and granisetron [3 mg] before TACE; days 2 and 3, intravenous dexamethasone [8 mg]) or a control regimen (day 1, intravenous placebo [saline] and granisetron [3 mg]; days 2 and 3, intravenous placebo). The primary endpoint was complete response, defined as the absence of grade ≥1 fever, anorexia, or nausea/vomiting according to the Common Terminology Criteria for Adverse Events (version 4.0) and no use of rescue therapy for 120 hours after TACE. A total of 120 patients between October 2010 and June 2013 were randomly assigned to treatment groups. Overall the complete response rate was greater with the dexamethasone regimen than with the control regimen (47.5%, 95% confidence interval 34.3%-60.9%, versus 10.2%, 95% confidence interval 3.8%-20.8%; P < 0.001). Cumulative incidences of fever, anorexia, and nausea/vomiting were higher in the control regimen group compared with the dexamethasone group (P < 0.001, P < 0.001, and P = 0.095, respectively). The dexamethasone regimen was generally well tolerated by HCC patients including those with well-controlled diabetes mellitus and those with hepatitis B virus infection. Conclusion: The dexamethasone regimen was more effective than the control regimen at preventing TACE-induced fever, anorexia, and nausea/vomiting in patients with HCC. (Hepatology 2018;67:575-585).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ogasawara S, Chiba T, Ooka Y, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology. 2017. PMID: 28746788. doi:10.1002/hep.29403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。